datopotamab deruxtecan - Robuta Search

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-08626&r=1 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin... Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or... datopotamab deruxtecan study plus carboplatin cisplatin https://www.businesswire.com/news/home/20231022739040/en/Datopotamab-Deruxtecan-Improved-Progression-Free-Survival-Versus-Chemotherapy-in-Patients-with-Previously-Treated-Non-Small-Cell-Lung-Cancer-in-TROPION-Lung01-Phase-3-Trial Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with... Datopotamab Deruxtecan Improved Progression-Free Survival Vs. Chemo in Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial progression free survival datopotamab deruxtecan in patients improved https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09124 Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable,... Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer datopotamab deruxtecan for the her2 negative trastuzumab https://www.healthday.com/healthpro-news/cancer/datopotamab-deruxtecan-improves-survival-in-triple-negative-breast-cancer Datopotamab Deruxtecan Improves Survival in TNBC For patients with previously untreated, locally recurrent inoperable or metastatic, advanced triple negative breast cancer, first-line datopotamab deruxtecan... datopotamab deruxtecan improves survival tnbc https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-08626 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin... Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or... datopotamab deruxtecan study plus carboplatin cisplatin https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-datopotamab-deruxtecan-for-breast-cancer-tropion-breast01 A trial of datopotamab deruxtecan for breast cancer (TROPION-Breast01) This trial compared datopotamab deruxtecan and standard chemotherapy for breast cancer. a trial datopotamab deruxtecan breast cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-datopotamab-deruxtecan-and-durvalumab-for-breast-cancer-tropion-breast04 A trial looking at datopotamab deruxtecan and durvalumab for breast cancer (TROPION-Breast04) This trial is comparing datopotamab deruxtecan and durvalumab with pembrolizumab and standard chemotherapy before surgery for breast cancer. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-datopotamab-deruxtecan-durvalumab-advanced-triple-negative-breast-cancer-diamond A trial looking at datopotamab deruxtecan and durvalumab for advanced triple negative breast cancer... This trial is comparing datopotamab deruxtecan with durvalumab and datopotamab deruxtecan for triple negative breast cancer. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-11062 Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain... Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain Metastasis her2 negative breast cancer https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive... Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable... phase iii study https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung... On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-03735&r=1 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for... Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-datopotamab-deruxtecan-with-or-without-durvalumab-triple-negative-breast-cancer-that-spread-or-come-back-tropionbreast05 A study of datopotamab deruxtecan with or without durvalumab for triple negative breast cancer that... This study is comparing datopotamab deruxtecan with or without durvalumab to chemotherapy and immunotherapy for breast cancer that has spread or come back. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-rilvegostomig-datopotamab-deruxtecan-non-small-cell-lung-cancer-spread-tropion-lung10 A trial looking at rilvegostomig and datopotamab deruxtecan for non small cell lung cancer that has... This trial is looking at rilvegostomig on its own or with datopotamab deruxtecan for non small cell lung cancer. non small cell lung cancer https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447&r=1 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive... Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable... phase iii study